Alzheimer’s disease impacts over 3 million families across the United States every year. Despite there currently being no effective treatment, various efforts are being made to tackle this disease. Using companion diagnostics, biomarkers can be used to monitor and predict patient response towards different drug treatments. In this case study, neurofilament light chain, a debris protein from axonal damage that may serve as a biomarker of neurodegeneration for Alzheimer’s disease, was quantified in human plasma, serum and cerebral spinal fluid on the Quanterix Simoa™ platform using the commercial Simoa NF-L Assay kit provided by Quanterix Simoa.
To download the full poster, click here
In association with Frontage